The future of immune checkpoint therapy
The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While ICIs produce durable responses in some patients most patients either do not benefit or develop resistance over time.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [6]
In the citing paper
“(2)Activation and inhibitory signals of T cells are mediated through CTLA-4 [229].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [229]
In the citing paper
“To activate or turn T cells “on,” both the TCR signal via CD3 (signal 1) and the CD28 costimulatory signal via B7 interactions (signal 2) are required (Fig. 1A).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [2]
In the citing paper
“Upon tumor growth, more immune cells appear, as natural killer (NK) cells, macrophages and dendritic cells (DCs) become part of the TME, while T cells are necessary for a proper antitumor immune response [98,99].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [99]
Citations
Cites
1 retracted
Targeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedImproved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Cited by
Items 101–200 of 419
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì, A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. (2017) · Nature · doi:10.1038/nature24673 · Cited by 627
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
Kim, O. Y., Park, H. T., Dinh, N. T. H., Choi, S. J., Lee, J., Kim, J. H., Lee, S.-W., & Gho, Y. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00729-8 · Cited by 616
Dynamics and specificities of T cells in cancer immunotherapy
Oliveira, G., & Wu, C. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00560-y · Cited by 616
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80008 · Cited by 613
Georgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 602
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès-Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 602
Porphyrin‐Based Metal–Organic Frameworks for Biomedical Applications
Chen, J., Zhu, Y., & Kaskel, S. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.201909880 · Cited by 597
Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Self-citationWang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05750 · Cited by 589
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18570-x · Cited by 553
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582
“9, eaak9670 (2017) 12 April 2017 may be reminiscent of findings in cancer patients receiving immune checkpoint blockade: Although the antitumoral responses can be marked and long-lasting in some cases, they typically involve only a minority of the patients (17).”
BackgroundLow and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Scheper, W., Kelderman, S., Fanchi, L. F., Linnemann, C., Bendle, G., de Rooij, M. A. J., Hirt, C., Mezzadra, R., Slagter, M., Dijkstra, K., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0266-5 · Cited by 576
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Resistance to PD1/PDL1 checkpoint inhibition
O'Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 572
Precision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1327 · Cited by 535
“Antibody therapy can be used to block the CTLA4 or PD-1 (PDCD1) checkpoints, releasing the T-cells to attack the tumor (71,72).”
BackgroundThe CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 557
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Lu, X., Horner, J. W., Paul, E., Shang, X., Troncoso, P., Deng, P., Jiang, S., Chang, Q., Spring, D. J., Sharma, P., et al. (2017) · Nature · doi:10.1038/nature21676 · Cited by 547
Self-citationAn HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521
“Due to the inhibitory role of checkpoint receptors on T cells, they are targets for immunotherapy (Sharma and Allison, 2015).”
BackgroundPalaskas, N., Lopez‐Mattei, J., Durand, J. B., Iliescu, C., & Deswal, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013757 · Cited by 535
Application of PD-1 Blockade in Cancer Immunotherapy
Wu, X., Gu, Z., Chen, Y., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 531
Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma
Ohashi, S., Miyamoto, S., Kikuchi, O., Goto, T., Amanuma, Y., & Muto, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.054 · Cited by 530
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Jung, H., Kim, H. S., Kim, J. Y., Sun, J.-M., Ahn, J. S., Ahn, M.-J., Park, K., Esteller, M., Lee, S.-H., & Choi, J. K. (2019) · Nature Communications · doi:10.1038/s41467-019-12159-9 · Cited by 529
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 526
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524
The gut microbiota influences anticancer immunosurveillance and general health
Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523
Aptamer-based targeted therapy
Zhu, G., & Chen, X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.005 · Cited by 522
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 522
Ott, P. A., Elez, E., Hiret, S., Kim, D.-W., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 521
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Isolation and characterization of exosomes for cancer research
Zhu, L., Sun, H.-T., Wang, S., Huang, S.-L., Zheng, Y., Wang, C.-Q., Hu, B.-Y., Qin, W., Zou, T.-T., Fu, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00987-y · Cited by 520
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Takenaka, M. C., Gabriely, G., Rothhammer, V., Mascanfroni, I. D., Wheeler, M. A., Chao, C.-C., Gutiérrez-Vázquez, C., Kenison, J., Tjon, E. C., Barroso, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0370-y · Cited by 517
Ott, P. A., Bang, Y.-J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J. M., Aung, K. L., Lopez, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5952 · Cited by 506
Lu, K., He, C., Guo, N., Chan, C., Ni, K., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b06663 · Cited by 505
Genetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
Huang, Q., Wu, X., Wang, Z., Chen, X., Wang, L., Lu, Y., Xiong, D., Liu, Q., Tian, Y., Lin, H., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.020 · Cited by 486
The tumour glyco-code as a novel immune checkpoint for immunotherapy
RodrÍguez, E., Schetters, S. T. T., & van Kooyk, Y. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.3 · Cited by 473
Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
Rodríguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C., & Demaria, S. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.06.001 · Cited by 497
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami-Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 495
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 490
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487
New and emerging targeted treatments in advanced non-small-cell lung cancer
Hirsch, F. R., Suda, K., Wiens, J., & Bunn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31473-8 · Cited by 487
George, S., Miao, D., Demetri, G. D., Adeegbe, D., Rodig, S. J., Shukla, S., Lipschitz, M., Amin-Mansour, A., Raut, C. P., Carter, S. L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.001 · Cited by 483
Hollern, D. P., Xu, N., Thennavan, A., Glodowski, C., Garcia-Recio, S., Mott, K. R., He, X., Garay, J. P., Carey-Ewend, K., Marron, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.028 · Cited by 478
SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
Veillette, A., & Chen, J. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.12.005 · Cited by 476
Liu, B., Hu, X., Feng, K., Gao, R., Xue, Z., Zhang, S., Zhang, Y., Corse, E., Hu, Y., Han, W., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00292-8 · Cited by 473
Yang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
Biomaterial-assisted targeted modulation of immune cells in cancer treatment
Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 467
Pyroptosis: a new paradigm of cell death for fighting against cancer
Tan, Y., Chen, Q., Li, X., Zeng, Z., Xiong, W., Li, G., Li, X., Yang, J., Xiang, B., & Yi, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01959-x · Cited by 467
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462
Neoantigen landscape dynamics during human melanoma–T cell interactions
Verdegaal, E. M. E., de Miranda, N. F. C. C., Visser, M., Harryvan, T., van Buuren, M. M., Andersen, R. S., Hadrup, S. R., van der Minne, C. E., Schotte, R., Spits, H., et al. (2016) · Nature · doi:10.1038/nature18945 · Cited by 461
Beyond immune checkpoint blockade: emerging immunological strategies
Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L., & Mak, T. W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00155-y · Cited by 461
Duan, X., Chan, C., Guo, N., Han, W., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09538 · Cited by 458
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 453
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
Wei, J., Long, L., Zheng, W., Dhungana, Y., Lim, S. A., Guy, C., Wang, Y., Wang, Y.-D., Qian, C., Xu, B., et al. (2019) · Nature · doi:10.1038/s41586-019-1821-z · Cited by 447
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
Strønen, E., Toebes, M., Kelderman, S., van Buuren, M. M., Yang, W., van Rooij, N., Donia, M., Böschen, M.-L., Lund-Johansen, F., Olweus, J., et al. (2016) · Science · doi:10.1126/science.aaf2288 · Cited by 445
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
mTORC1 and mTORC2 in cancer and the tumor microenvironment
Kim, L. C., Cook, R. S., & Chen, J. (2017) · Oncogene · doi:10.1038/onc.2016.363 · Cited by 444
Therapeutic targeting of trained immunity
Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A., & Netea, M. G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0025-4 · Cited by 443
The immunology of renal cell carcinoma
Díaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 442
Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440
Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 440
IDO1 in cancer: a Gemini of immune checkpoints
Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 437
Collagen density regulates the activity of tumor-infiltrating T cells
Kuczek, D. E., Larsen, A. M. H., Thorseth, M.-L., Carretta, M., Kalvisa, A., Siersbæk, M. S., Simões, A. M. C., Roslind, A., Engelholm, L. H., Noessner, E., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0556-6 · Cited by 435
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Hsu, J.-M., Xia, W., Hsu, Y.-H., Chan, L.-C., Yu, W.-H., Cha, J.-H., Chen, C.-T., Liao, H.-W., Kuo, C.-W., Khoo, K.-H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04313-6 · Cited by 434
Complement in cancer: untangling an intricate relationship
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A., & Lambris, J. D. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.97 · Cited by 425
T‐cell exhaustion in HIV infection
Fenwick, C., Joo, V., Jacquier, P., Noto, A., Banga, R., Perreau, M., & Pantaleo, G. (2019) · Immunological Reviews · doi:10.1111/imr.12823 · Cited by 425
Perrot, I., Michaud, H.-A., Giraudon-Paoli, M., Augier, S., Docquier, A., Gros, L., Courtois, R., Déjou, C., Jecko, D., Becquart, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.091 · Cited by 423
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Zak, K. M., Grudnik, P., Guzik, K., Zieba, B. J., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8730 · Cited by 422
Gubin, M. M., Esaulova, E., Ward, J. P., Malkova, O. N., Runci, D., Wong, P., Noguchi, T., Arthur, C. D., Meng, W., Alspach, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.030 · Cited by 419
Jiang, S.-S., Xie, Y.-L., Xiao, X.-Y., Kang, Z.-R., Lin, X.-L., Zhang, L., Li, C.-S., Qian, Y., Xu, P.-P., Leng, X.-X., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.04.010 · Cited by 419
Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells
Saha, T., Dash, C., Jayabalan, R., Khiste, S., Kulkarni, A., Kurmi, K., Mondal, J., Majumder, P. K., Bardia, A., Jang, H. L., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-021-01000-4 · Cited by 418
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731798 · Cited by 417
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Mosely, S. I. S., Prime, J. E., Sainson, R. C. A., Koopmann, J.-O., Wang, D. Y. Q., Greenawalt, D. M., Ahdesmaki, M. J., Leyland, R., Mullins, S., Pacelli, L., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0114 · Cited by 415
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Supramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406
Self-citationMolecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 410
m 6 A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy
Wang, L., Hui, H., Agrawal, K., Kang, Y., Li, N., Tang, R., Yuan, J., & Rana, T. M. (2020) · The EMBO Journal · doi:10.15252/embj.2020104514 · Cited by 407
Reardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., Jones, K. L., Conway, A. S., Liao, X., Zhou, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0151 · Cited by 405
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
KATOH, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
X-ray-activated nanosystems for theranostic applications
Chen, X., Song, J., Chen, X., & Yang, H. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00921j · Cited by 401
Immunosuppressive cells in tumor immune escape and metastasis
Liu, Y., & Cao, X. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1376-x · Cited by 400
Immunosuppressive Mechanisms of Regulatory B Cells
Catalán, D., Mansilla, M. A., Ferrier, A., Soto, L., Oleinika, K., Aguillón, J. C., & Aravena, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611795 · Cited by 399
Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas
Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3292 · Cited by 395
“Having observed substantial differences in T-cells infiltrating the primary tumors arising from implanted epithelial versus mesenchymal carcinoma cells, we asked whether these tumors would differ in their susceptibility to checkpoint blockade therapy (10, 11).”
BackgroundHuinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386
Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
Suzuki, S., Ishikawa, N., Konoeda, F., Seki, N., Fukushima, S., Takahashi, K., Uhara, H., Hasegawa, Y., Inomata, S., Otani, Y., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004359 · Cited by 392
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Cai, L., Li, Y., Tan, J., Xu, L., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01499-1 · Cited by 391
Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D. Y., Shin, D. S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.005 · Cited by 390
Metadata
- Authors
- Sharma, P., & Allison, J. P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Sharma, Padmanee
- Allison, James P.
- Venue
- Science
- Published
- 2015-04-03
- Volume
- 348
- Issue
- 6230
- Pages
- 56-61
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2060070314
- Cited by
- 4,878
- References
- 70
- Citations by year
- 2026: 311 · 2025: 372 · 2024: 398 · 2023: 462 · 2022: 473 · 2021: 576 · 2020: 569 · 2019: 455 · 2018: 444 · 2017: 401 · 2016: 294 · 2015: 113
- FWCI
- 44.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Prevention Research in Texas
- PCF Challenge Grant in Immunology
- NCI/NIH (1-R01 CA1633793-01)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitors, cancer immunotherapy, tumor microenvironment, antitumor immunity, T cell regulation, combination therapy, sustained remission
- MeSH terms
- Ipilimumab, Nivolumab, Antibodies, Monoclonal, Antineoplastic Agents, Combined Modality Therapy, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Signal Transduction, Biomarkers, Pharmacological, Tumor Microenvironment, Inducible T-Cell Co-Stimulator Protein, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.